All News
15 September 2017 The RheumNow Week in Review
The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report discusses metabolic syndrome in lupus, bisphosphonate holidays, vasculitis and vascular inflammation, vaccination, and the repeated wonders of Vitamin D.
Read ArticleNew Recommendations on Biosimilar Use
The introduction of a growing number of biosimilars into the market poses a substantial change in cost of care for patients with inflammatory rheumatologic disorders.
Read ArticleAdalimumab Biosimilars Adding Up
Reuters reports that yet another adalimumab biosimilar has been approved by European Union regulators.
The new drug is named Imraldi, and is manufactured by Samsung Bioepis, a company who has several biosimilars approved or in development for worldwide use.
Read ArticleKids with Crohn's have Profound MSK Deficits - but No Increase in Fractures
Crohn’s disease (CD), a chronic inflammatory condition of the gastrointestinal tract, is also known for its propensity to affect the musculoskeletal system.
Read ArticlePediatric Consensus on Comorbidity Assessments
Comorbidity is a serious consequence or confounder in patients with inflammatory diseases. This has been well described in both psoriatic and rheumatoid disease.
Read ArticleNOR-SWITCH Study Validates Biosimilar Use in Multiple Indications
Lancet reports the results of the NOR-SWITCH study - a trial performed in Norway as biosimilars were being introduced.
Read ArticleNSAIDs Increase Risk of Acute Myocardial Infarction
Using data from Canadian and European healthcare databases, the BMJ has reported that all NSAIDs, including celecoxib and naproxen, increase the risk of acute myocardial infarction.
Read ArticleIncreased Comorbidities in Rheumatoid Arthritis
A population based study from Taiwan examined the frequencies of comorbidities in a rheumatoid arthritis (RA) population.
Read ArticleTofacitinib Effective in Ulcerative Colitis
Tofacitinib is currently approved for use in rheumatoid arthritis, but is being studied in numerous other inflammatory conditons including spondylitis, psoriasis, and psoriatic arthritis, and has also been studied in patients with ulcerative colitis (UC).
Read ArticleVenous Thromboembolism Risk Factors in ANCA-Associated Vasculitis
A retrospective analysis of four European vasculitis trials analyzes the risk venous thromboembolism (VTE) with ANCA-associated vasculitis and shows that CRP, cutaneous and GI involvement and baseline creatinine were most associated with VTE risk.
Read ArticleAnti-IL-23 Therapy Effective in Crohn's Disease
Lancet has reported the results of risankizumab, an interleukin-23 (IL-23) inhibitor, in Crohn's disease. Risankizumab is a humanised monoclonal antibody targeting the p19 subunit of interleukin-23, and is being developed for Crohn's disease.
Read ArticleCelecoxib Plus PPI Preferred in High Risk Patients
When do the risks outweigh the benefits of NSAIDs use, especially in those with prior cardiovascular and gastrointestinal events? The CONCERN study has tested the effects of proton-pump inhibitor (PPI) in preventing GI bleeds when using NSAIDs and ASA.
Read ArticleThe RheumNow Week in Review – 31 March 2017
Dr. Jack Cush reviews highlights from the news and Advances in Targeted Therapies meeting in Mandelieu, France:
Tweeting this week from Advances in Targeted Therapies #ATT2017 in Mandelieu, France.
Read ArticleTNF Inhibitor Induced Psoriasis
Tumor necrosis factor-α inhibitors (TNFi) rarely have been reported to induce new-onset psoriasis.
Read ArticleLupus Hepatitis and Lupoid Hepatitis Reviewed
SLE-related hepatitis (“lupus hepatitis”) and “lupoid hepatitis” are 2 different diseases. The term "lupoid hepatitis", now known as autoimmune hepatitis (AIH), was first coined in 1959. AIH was initially called “lupoid hepatitis” by MacKay. A review by Adiga and Nugent reviews, defines and distinguishes between lupus-related hepatitis and lupoid hepatitis.
Read ArticleMethotrexate and Folate Use by Rheumatologists - Survey Results
The February 2017 RheumNow “Live Vote” surveyed US and non-US rheumatologists about their beliefs and practices regarding folic acid and methotrexate (MTX) use. A total of 495 responses were tabulated in 2 weeks. Here are the results, and comments from Dr. Kremer on his preferred answers to these questions.
Read ArticleThe RheumNow Week in Review – 24 February 2017
Dr. Jack Cush reviews highlights from the past week on RheumNow.com:
Read ArticleThe RheumNow Week in Review – 17 February 2017
Dr. Jack Cush reviews this week's news and information from the 2017 RWCS meeting in Maui.
Read ArticleCrohn's Arthritis Linked to E. Coli Infection
Articular manifestations of Crohn's disease affects a significant number of patients with either oligoarticular or RA-like polyarthritis or spondyloarthritis.
Read Article


